Jefferies analyst James Vane-Tempest initiated coverage of Oxford Biomedica (OXBDF) with a Buy rating and 566 GBp price target Despite its strong track record of excellence, commercial experience, and other key metrics for customers, Oxford shares have weakened year-to-date, the analyst tells investors in a research note. While shares offer upside should guidance be achieved, there is limited visibility in an uncertain market, Jefferies added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OXBDF:
- Oxford Biomedica Strengthens Leadership with New Board Appointment
- Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary
- Oxford BioMedica Achieves Full Ownership of US Subsidiary
- Oxford Biomedica Director Increases Stake with Share Purchase
- Oxford Biomedica Announces AGM Results and Board Changes